Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Receives Consensus Recommendation of “Hold” from Analysts

Share on StockTwits

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has been assigned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $23.88.

Several research analysts have recently issued reports on ADMS shares. HC Wainwright cut their price target on Adamas Pharmaceuticals from $40.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, May 28th. Evercore ISI reiterated a “buy” rating and issued a $55.00 price target on shares of Adamas Pharmaceuticals in a report on Monday, August 12th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Cowen set a $5.00 price target on Adamas Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, August 9th.

Adamas Pharmaceuticals stock opened at $6.13 on Friday. The firm has a 50-day moving average price of $6.08 and a 200-day moving average price of $6.77. The firm has a market capitalization of $170.23 million, a PE ratio of -1.26 and a beta of 1.69. The company has a current ratio of 7.27, a quick ratio of 7.05 and a debt-to-equity ratio of 3.05. Adamas Pharmaceuticals has a 12-month low of $4.20 and a 12-month high of $23.36.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.08. The business had revenue of $12.69 million during the quarter, compared to the consensus estimate of $12.62 million. Adamas Pharmaceuticals had a negative return on equity of 149.97% and a negative net margin of 241.41%. As a group, sell-side analysts predict that Adamas Pharmaceuticals will post -3.74 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of ADMS. Quantamental Technologies LLC bought a new stake in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $25,000. BNP Paribas Arbitrage SA acquired a new position in Adamas Pharmaceuticals during the first quarter worth approximately $33,000. PNC Financial Services Group Inc. acquired a new position in Adamas Pharmaceuticals during the first quarter worth approximately $43,000. Advisor Group Inc. increased its position in Adamas Pharmaceuticals by 53.4% during the second quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 3,900 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Adamas Pharmaceuticals by 63.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock worth $91,000 after buying an additional 6,000 shares during the last quarter. 76.94% of the stock is currently owned by institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Recommended Story: The Discount Rate – What You Need to Know

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Reviewing Seacoast Commerce Banc  & First Community
Reviewing Seacoast Commerce Banc & First Community
Financial Review: CAPITA GRP/ADR  vs. SPAR Group
Financial Review: CAPITA GRP/ADR vs. SPAR Group
Financial Contrast: Jerash Holdings   and Its Competitors
Financial Contrast: Jerash Holdings and Its Competitors
UPM-Kymmene  vs. Suzano  Financial Contrast
UPM-Kymmene vs. Suzano Financial Contrast
Critical Comparison: Atlatsa Resources  and Rio Tinto
Critical Comparison: Atlatsa Resources and Rio Tinto
Centric Brands  and Its Competitors Critical Analysis
Centric Brands and Its Competitors Critical Analysis


© 2006-2019 Ticker Report